{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:03:26Z","timestamp":1793113406436,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":2133,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1124\/jpet.118.253864","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:06:46Z","timestamp":1546978006000},"page":"462-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension"],"prefix":"10.1016","volume":"368","author":[{"given":"Frederic","family":"Trensz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bortolamiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kramberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Hadana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Delahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vezzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mentzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Clozel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Iglarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.253864_bib44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/pds.3748","article-title":"Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort","volume":"24","author":"Abbas","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/jpet.118.253864_bib1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/HJH.0b013e328338bb8b","article-title":"Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice","volume":"28","author":"Amiri","year":"2010","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.118.253864_bib2","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jacc.2008.12.050","article-title":"Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea","volume":"53","author":"Belaidi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.118.253864_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0272-6386(96)90366-2","article-title":"Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney","volume":"27","author":"Benigni","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.118.253864_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.HYP.0000088363.65943.6C","article-title":"ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension","volume":"42","author":"Callera","year":"2003","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.33.2.753","article-title":"Role of endothelin in the increased vascular tone of patients with essential hypertension","volume":"33","author":"Cardillo","year":"1999","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005344-200307000-00008","article-title":"Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat","volume":"42","author":"Ding","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.118.253864_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.CIR.103.2.263","article-title":"Regulation of plasma endothelin by salt in salt-sensitive hypertension","volume":"103","author":"Elijovich","year":"2001","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/01.HYP.28.4.652","article-title":"Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension","volume":"28","author":"Ergul","year":"1996","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/01.HYP.32.5.862","article-title":"Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion","volume":"32","author":"Ferri","year":"1998","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib10","unstructured":"Food and Drug Administration (2018) Hypertension: conducting studies of drugs to treat patients on a background of multiple antihypertensive drugs guidance for industry. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM613176.pdf"},{"key":"10.1124\/jpet.118.253864_bib11","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253864_bib12","doi-asserted-by":"crossref","first-page":"F58","DOI":"10.1152\/ajprenal.00209.2004","article-title":"A high-salt diet stimulates thick ascending limb eNOS expression by raising medullary osmolality and increasing release of endothelin-1","volume":"288","author":"Herrera","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.118.253864_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ASN.0000042165.63601.65","article-title":"ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease","volume":"14","author":"Hocher","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.118.253864_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/hy0202.103442","article-title":"Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro","volume":"39","author":"Iglarz","year":"2002","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.253864_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/CS20100222","article-title":"At the heart of tissue: endothelin system and end-organ damage","volume":"119","author":"Iglarz","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/jpet.118.253864_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FJC.0000000000000283","article-title":"Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA versus ETB receptors and on the functionality of endothelial ETB receptors","volume":"66","author":"Iglarz","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.118.253864_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/hc3101.092201","article-title":"Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure","volume":"104","author":"Iwanaga","year":"2001","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0192623311413788","article-title":"Morphologic aspects of rodent cardiotoxicity in a retrospective evaluation of National Toxicology Program studies","volume":"39","author":"Jokinen","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.118.253864_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1124\/jpet.118.253864_bib21","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.99.9.1242","article-title":"Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney","volume":"99","author":"Kakoki","year":"1999","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"10.1124\/jpet.118.253864_bib23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1124\/jpet.118.253864_bib43","doi-asserted-by":"crossref","first-page":"R1906","DOI":"10.1152\/ajpregu.2001.280.6.R1906","article-title":"Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure","volume":"280","author":"Liu","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.118.253864_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0014-5793(93)80384-7","article-title":"Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma","volume":"333","author":"L\u00f6ffler","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.118.253864_bib25","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.HYP.36.2.282","article-title":"Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage","volume":"36","author":"Muller","year":"2000","journal-title":"Hypertension"},{"key":"10.1124\/jpet.118.253864_bib27","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253864_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004872-200403000-00026","article-title":"Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt","volume":"22","author":"Richer-Giudicelli","year":"2004","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.118.253864_bib29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1172\/JCI117440","article-title":"Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex","volume":"94","author":"Rossi","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.118.253864_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0008-6363(99)00110-8","article-title":"Interactions between endothelin-1 and the renin-angiotensin-aldosterone system","volume":"43","author":"Rossi","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.118.253864_bib31","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/00004872-199816121-00007","article-title":"Endothelin and endothelin antagonists in hypertension","volume":"16","author":"Schiffrin","year":"1998","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.118.253864_bib32","first-page":"199","article-title":"Endothelin: role in hypertension","volume":"31","author":"Schiffrin","year":"1998","journal-title":"Biol Res"},{"key":"10.1124\/jpet.118.253864_bib33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.lfs.2012.03.032","article-title":"Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist","volume":"91","author":"Sen","year":"2012","journal-title":"Life Sci"},{"key":"10.1124\/jpet.118.253864_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.fjc.0000210070.47205.16","article-title":"Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance","volume":"47","author":"Shemyakin","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.118.253864_bib35","first-page":"S87","article-title":"Single-and multiple-dose safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects","volume":"103","author":"Sidharta","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.118.253864_bib36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0002-9149(99)00912-1","article-title":"Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins","volume":"85","author":"S\u00fctsch","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.118.253864_bib37","doi-asserted-by":"crossref","first-page":"e003381","DOI":"10.1161\/CIRCHEARTFAILURE.116.003381","article-title":"Dual endothelin-A\/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction","volume":"9","author":"Valero-Munoz","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1124\/jpet.118.253864_bib38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.253864_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/01.CIR.97.8.752","article-title":"Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade","volume":"97","author":"Verhaar","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/jpet.118.253864_bib40","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.ASN.0000017902.77985.84","article-title":"Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes","volume":"13","author":"Wang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.118.253864_bib41","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1124\/jpet.118.253864_bib42","first-page":"103","article-title":"Vascular and cardiac actions of aldosterone and spironolactone","volume":"80","author":"Zannad","year":"1991","journal-title":"Z Kardiol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652426105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652426105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.253864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:55:53Z","timestamp":1739976953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652426105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S002235652426105X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.253864","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734831610.793578607","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.253864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}